Datar Cancer Genetics Launches Exacta AI to Offer Personalized Treatment Options for Cancer Patients
Shots:
- Datar Cancer Genetics has introduced Exacta AI (multi-analyte platform) to provide ~10 evidence-based drug combinations as a treatment for cancer patients who have exhausted SoC options
- Exacta AI integrates 360° tumor work-up with AI-driven analysis of complex tumor interactome data to assess drug interactions, toxicity, & side effects for ADCs, CPIs, targeted therapies, repurposed drugs, plus endocrine & CT agents.
- Additionally, in a retrospective in-silico study, Exacta AI has generated 7–10 therapy options for 265 pts with drug-resistant solid organ cancers & no SoC option, while standard molecular profiling provided only ~2 options for 15% pts
Ref: PR Newswire | Image: Datar Cancer Genetics
Related News:- Life Spine Receives US FDA’s 510(k) Clearance for ProLift Pivot Expandable Spacer System
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies, FDA, EMA, and biosimilar approvals. He can be contacted at connect@pharmashots.com
